-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, M+kxvHMl0axoOJhCqrOWkrpV2Ez2KZy4zBMgjw/6p/m8yntTFO/vsnxOdqSdFgDh 5IqFZipWv7QDc3P9D0NX8Q== 0001144204-05-015115.txt : 20050513 0001144204-05-015115.hdr.sgml : 20050513 20050513095447 ACCESSION NUMBER: 0001144204-05-015115 CONFORMED SUBMISSION TYPE: 13F-HR PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20050331 FILED AS OF DATE: 20050513 DATE AS OF CHANGE: 20050513 EFFECTIVENESS DATE: 20050513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BAKER BROS ADVISORS LLC CENTRAL INDEX KEY: 0001263508 IRS NUMBER: 134093645 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 13F-HR SEC ACT: 1934 Act SEC FILE NUMBER: 028-10519 FILM NUMBER: 05826628 BUSINESS ADDRESS: STREET 1: 667 MADISON AVENUE STREET 2: 17TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10021 BUSINESS PHONE: 2125212418 13F-HR 1 v017861_13fhr.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 13F FORM 13F COVER PAGE Report for the Calendar Year or Quarter Ended: March 31, 2005 Check here if Amendment [ ]; Amendment Number: _____ This Amendment (Check only one.): [ ] is a restatement. [ ] adds new holdings entries. Institutional Investment Manager Filing this Report: Name: Baker Bros. Advisors, LLC -------------------------------------------- Address: 667 Madison Avenue, 17th Floor -------------------------------------------- New York, NY 10021-8029 -------------------------------------------- Form 13F File Number: 28-10519 The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form. Person Signing this Report on Behalf of Reporting Manager: Name: Leo Kirby -------------------------------------------- Title: Chief Financial Officer -------------------------------------------- Phone: 212-521-2418 -------------------------------------------- Signature, Place, and Date of Signing: /s/ Leo Kirby New York, N.Y. May 13, 2005 - -------------------------- --------------------------- ---------------------- [Signature] [City, State] [Date] Report Type (Check only one.): [X] 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.) [_] 13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).) [_] 13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).) List of Other Managers Reporting for this Manager: None FORM 13F SUMMARY PAGE Report Summary: Number of Other Included Managers: 0 ----------- Form 13F Information Table Entry Total: 53 ----------- Form 13F Information Table Entry Value: 269,067 ----------- (thousands) List of Other Included Managers: None
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8 VOTING AUTHORITY -------------------- TITLE OF VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER NAME OF ISSUER CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGERS SOLE SHARED NONE - ----------------- ----- ----- -------- ------- --- ---- ---------- -------- ---- ------ ---- Acadia Pharmaceuticals Inc. COM 004225108 798 115,703 SH SOLE 115,703 Adolor Corp. COM 00724X102 14,969 1,508,983 SH SOLE 1,508,983 Alexion Pharmaceuticals Inc. COM 015351109 8,218 379,338 SH SOLE 379,338 Alkermes Inc. COM 01642T108 808 77,859 SH SOLE 77,859 Allos Therapeutics Inc. COM 019777101 2,672 1,297,108 SH SOLE 1,297,108 Amgen Inc. COM 031162100 7,274 124,954 SH SOLE 124,954 Amylin Pharmaceuticals Inc. COM 032346108 6,660 380,782 SH SOLE 380,782 Anadys Pharmaceuticals Inc. COM 03252Q408 322 43,799 SH SOLE 43,799 Array Biopharma Inc. COM 04269X105 2,664 379,974 SH SOLE 379,974 Atherogenics Inc. COM 047439104 730 55,789 SH SOLE 55,789 Autoimmune Inc. COM 052776101 26 26,100 SH SOLE 26,100 Barrier Therapeutics Inc. COM 06850R108 5,784 373,389 SH SOLE 373,389 Biocryst Pharmaceuticals Inc. COM 09058V103 7,365 1,597,603 SH SOLE 1,597,603 Biogen Idec Inc. COM 09062X103 690 20,000 SH SOLE 20,000 Critical Therapeutics Inc. COM 22674T105 4,507 663,779 SH SOLE 663,779 Cytokinetics Inc. COM 23282W100 776 118,300 SH SOLE 118,300 Dynavax Technologies Corp. COM 268158102 276 59,100 SH SOLE 59,100 GTXI Inc. Del COM 40052B108 2,915 320,297 SH SOLE 320,297 Incyte Corp. COM 45337C102 22,635 3,314,070 SH SOLE 3,314,070 Inhibitex Inc. COM 45719T103 4,127 677,730 SH SOLE 677,730 Insmed Inc. COM 457669208 42 48,900 SH SOLE 48,900 Intermune Inc. COM 45884X103 2,689 244,414 SH SOLE 244,414 Intrabiotics Pharmaceuticals COM 46116T506 3,408 946,617 SH SOLE 946,617 Ligand Pharmaceuticals Inc. COM 53220K207 814 138,357 SH SOLE 138,357 Medarex Inc. COM 583916101 7,428 1,041,780 SH SOLE 1,041,780 Metabasis Therapeutics Inc. COM 59101M105 1,760 517,710 SH SOLE 517,710 Myogen Inc. COM 62856E104 9,362 1,186,505 SH SOLE 1,186,505 Myriad Genetics Inc. COM 62855J104 697 37,888 SH SOLE 37,888 Nastech Pharmaceutical Inc. COM 631728409 2,079 210,456 SH SOLE 210,456 Nektar Therapeutics COM 640268108 174 12,500 SH SOLE 12,500 Neose Technologies Inc. COM 640522108 1,935 750,000 SH SOLE 750,000 Neurogen Corp. COM 64124E106 37,708 5,325,999 SH SOLE 5,325,999 Nitromed Inc. COM 654798503 2,332 134,700 SH SOLE 134,700 Nuvelo Inc. COM 67072M301 3,900 600,000 SH SOLE 600,000 Onyx Pharmaceuticals Inc. COM 683399109 4,613 147,154 SH SOLE 147,154 Pharmacyclics Inc. COM 716933106 2,726 339,452 SH SOLE 339,452 Pozen Inc. COM 73941U102 408 78,400 SH SOLE 78,400 Praecis Pharmaceuticals Inc. COM 739421105 53 50,100 SH SOLE 50,100 Seattle Genetics Inc. COM 812578102 4,437 863,179 SH SOLE 863,179 Senomyx Inc. COM 81724Q107 10,077 846,104 SH SOLE 846,104 Sequenom Inc. COM 817337108 52 48,881 SH SOLE 48,881 Theravance Inc. COM 88338T104 7,498 410,869 SH SOLE 410,869 Transkaryotic Therapies Inc. COM 893735100 2,321 92,961 SH SOLE 92,961 Trimeris Inc. COM 896263100 40,563 3,602,369 SH SOLE 3,602,369 Vicuron Pharmaceuticals Inc. COM 926471103 195 12,400 SH SOLE 12,400 Virologic Inc. COM 92823R201 953 398,619 SH SOLE 398,619 Viropharma Inc. COM 928241108 24 10,111 SH SOLE 10,111 Xcyte Therapies Inc. PFD CV EXCH 98389F408 864 95,500 SH SOLE 95,500 Incyte Genomics Notes 5.5% 2/01/2007 CONV BONDS 45337CAC6 2,497 2,500,000 PRN SOLE 2,500,000 Incyte Genomics Notes 3.5% 2/15/2011 CONV BONDS 45337CAE2 3,515 4,000,000 PRN SOLE 4,000,000 Regeneron Conv Notes 5.5% 10/17/08 (144A) CONV BONDS 75886FAA5 11,305 12,322,000 PRN SOLE 12,322,000 Regeneron Conv Notes 5.5% 10/17/08 CONV BONDS 75886FAB3 4,588 5,000,000 PRN SOLE 5,000,000 Valeant Conv Notes 3.0% 08/16/2010 CONV BONDS 91911XAB0 3,835 4,000,000 PRN SOLE 4,000,000
-----END PRIVACY-ENHANCED MESSAGE-----